THE NUMBER OF SHARES IN SCN INCREASED IN AUGUST

(NGM: SCN)

Through the share issue which was carried out during May-June, the number of shares in Scandinavian Clinical Nutrition AB (SCN) increased from 14,790,724 to 16,023,284 shares during August, 2008.

The company only has one class of shares, and the number of voting rights is therefore the same as the number of shares in the company.

This information is published with reference to chapter 4, section 9 in the Swedish Financial Instruments Trading Act.

For more information, please contact:

Thomas Christensen, CEO, tc@scnutrition.com, +47 922 55 444

Ulf Söderberg, Chairman of the Board, us@scnutrition.com, +46 708 13 22 81

Scandinavian Clinical Nutrition AB (publ) works in R&D and distribution of clinically tested, scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as CUUR, Coldizin, Immulina, Membra7 and Ledactin. Core competence and strategic alliances, within both R&D and sales, in combination with innovative and clinically proven products, create good conditions for profitable growth both in Sweden and internationally. The shares of SCN are traded under the ticker “SCN” on Oslo Axess (www.osloaxess.no) and NGM Equity (www.ngm.se). For more information, please visit www.scnutrition.com.